ATOS — Atossa Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $126.54m
- $68.68m
- 29
- 26
- 40
- 21
Annual income statement for Atossa Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 14.6 | 20.5 | 27.7 | 34.4 | 29.3 |
| Operating Profit | -14.6 | -20.5 | -27.7 | -34.4 | -29.3 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -17.8 | -20.6 | -27 | -30.1 | -25.5 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -17.8 | -20.6 | -27 | -30.1 | -25.5 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -17.8 | -20.6 | -27 | -30.1 | -25.5 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -22.3 | -20.6 | -27 | -30.1 | -25.5 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.97 | -0.176 | -0.213 | -0.215 | -0.189 |